Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
Genmab (GMAB) Stock Price & Analysis
457 Followers
GMAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$26.32 - $42.72
Previous Close$29.72
Volume721.27K
Average Volume (3M)568.73K
Market Cap
$19.58B
Enterprise Value$15.65B
Total Cash (Recent Filing)kr28.14B
Total Debt (Recent Filing)kr770.00M
Price to Earnings (P/E)24.4
Beta0.71
Next Earnings
Aug 01, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.22
Shares Outstanding660,745,350
10 Day Avg. Volume567,338
30 Day Avg. Volume568,725
Standard Deviation0.10
R-Squared0.28
Alpha0.00307
Financial Highlights & Ratios
Price to Book (P/B)0.60
Price to Sales (P/S)1.11
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$39.75Price Target Upside33.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Genmab News
PremiumCompany Announcements
Genmab A/S Details Capital and Corporate Structure
PremiumCompany Announcements
Genmab A/S Capital Boosted by Warrant Exercises
PremiumCompany Announcements
Genmab Advances Share Buy-back Program
PremiumCompany Announcements
Genmab’s Strong Q1 Financial Growth and FDA FocusBulls Say, Bears Say
Bulls Say
Drug ApprovalTIVDAK receives full FDA approval for the treatment of patients with recurrent or metastatic cervical cancer.
Financial PerformanceGenmab recorded diluted net income significantly above forecast, demonstrating strong financial performance.
Regulatory MilestoneGenmab's sBLA for 3L+ FL has been granted priority review by the FDA.
Bears Say
Earnings MissGenmab recorded diluted net income of DKK66.02 per share vs. forecast diluted net income of DKK78.51 per share.
Financial PerformanceGenmab reported a slight decrease in its total revenue compared to the previous quarter.
Royalty IssuesGenmab's royalties are reduced for its share of Janssen's royalty payments made to Halozyme for Darzalex, impacting their total royalty income.
---
Ownership Overview
0.00%
Insiders
1.85% Mutual Funds
0.92% Other Institutional Investors
97.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GMAB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was $26.32 and its highest was $42.72 in the past 12 months.
What is Genmab A/S’s market cap?
Currently, no data Available
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Aug 01, 2024 which is in 84 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on May 02, 2024. The company reported $0.291 earnings per share for the quarter, beating the consensus estimate of $0.172 by $0.119.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 661,229,600 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of $0.291 in its last earnings report, beating expectations of $0.172. Following the earnings report the stock price went down -3.583%.
Which hedge fund is a major shareholder of Genmab A/S?
Among the largest hedge funds holding Genmab A/S’s share is Antipodes Partners Ltd. It holds Genmab A/S’s shares valued at 6M.
---
Genmab Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.75 (33.75% Upside)
$39.75 (33.75% Upside)
Blogger Sentiment
Bullish
GMAB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 204.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.42%
12-Months-Change
Fundamentals
Return on Equity
18.32%
Trailing 12-Months
Asset Growth
19.81%
Trailing 12-Months
Company Description
Genmab A/S
Genmab A/S is an international biotech company. It is specialized in creating and developing differentiated antibody therapeutics for the treatment of cancer. The company currently markets DARZALEX monoclonal antibody for the treatment of patients with multiple myeloma and Arzerra monoclonal antibody for the treatment of chronic lymphocytic leukemia.
---
GMAB Company Deck
---
GMAB Earnings Call
Q1 2024
0:00 / 0:00
---
GMAB Stock 12 Month Forecast
Average Price Target
$39.75
▲(33.75% Upside)
Technical Analysis
Best Analysts Covering GMAB
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-7.20%
reiterated a buy rating 7 days ago
Copying Asthika Goonewardene's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -7.20% per trade.
---